84
Participants
Start Date
February 27, 2018
Primary Completion Date
February 25, 2021
Study Completion Date
February 17, 2022
Itacitinib
Itacitinib administered orally once daily at the protocol-defined dose.
Calcineurin inhibitor
The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
Memorial Sloan Kettering Cancer Center, New York
Azienda Ospedaliera San Gerardo Di Monza, Monza
University of Maryland - Greenebaum Cancer Center, Baltimore
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii (Presidio Papa Giovanni Xxiii), Bergamo
Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo, Pavia
Hospital Puerta de Hierro, Majadahonda
Winship Cancer Institute of Emory University, Atlanta
The Ohio State University, Columbus
Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu, Nantes
Hospital Clinico Universitario de Valencia, Valencia
Froedtert Hospital and the Medical College of Wisconsin, Milwaukee
Chu Vandoeuvre-Les-Nancy, Hopital Brabois, Vandœuvre-lès-Nancy
Chru de Lille Hopital Claude Huriez, Lille
Loyola University Medical Center, Maywood
Washington University School of Medicine, St Louis
Anschutz Cancer Pavilion - University of Colorado, Aurora
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
Lead Sponsor
Incyte Corporation
INDUSTRY